

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/963,732	09/26/2001	Fu-Pao Tsao	LP/V-31596A	9316
75	90 07/17/2004		EXAM	INER
Thomas Hoxid	:		PAK, JO	OHN D
Novartis Corpore Patent and Trad			ART UNIT	PAPER NUMBER
564 Morris Ave	-		1616	
Summit, NJ 0	7901-1027	DATE MAILED: 07/17/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

7	•	Application No.	Applicant(s)
		09/963,732	TSAO, FU-PAO
	Office Action Summary	Examiner	Art Unit
		JOHN D PAK	1616
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address
THE - Exter safter - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. neions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) deye, a reply period for reply is specified above, the maximum statutory period ware to reply within the set or extended period for reply with, by statute, reply received by the Office isater than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	16(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days till apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).
Status			
1)⊠	Responsive to communication(s) filed on 12 M	arch 2004.	
2a)⊠	This action is FINAL. 2b) This	action is non-final.	
3)	Since this application is in condition for allower	•	
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.
Disposit	ion of Claims		
4)⊠	Claim(s) 1-16 is/are pending in the application.		
	4a) Of the above claim(s) is/are withdraw	vn from consideration.	
5)	Claim(s) is/are allowed.		
6)⊠	Claim(s) <u>1-16</u> is/are rejected.		
	Claim(s) 2 and 12 is/are objected to.		•
8)	Claim(s) are subject to restriction and/o	r election requirement.	
Applicati	ion Papers		
9)[The specification is objected to by the Examine	r.	
10)	The drawing(s) filed on is/are: a) acc	epted or b) objected to by the l	Examiner.
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	37 CFR 1.85(a).
	Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is ob	jected to. See 37 CFR 1.121(d).
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.
Priority (under 35 U.S.C. § 119		
12)	Acknowledgment is made of a claim for foreign All b) Some * c) None of:	. ,)-(d) or (f).
	1. Certified copies of the priority documents		
	2. Certified copies of the priority documents	• •	
	 Copies of the certified copies of the prior application from the International Bureau 	·	ou in this National Stage
* 5	See the attached detailed Office action for a list	` ` ''	ed.
	occurs and control control to the portion of the po	or the bording topics hat readily	
Attachmen			
	ce of References Cited (PTO-892)	4) Interview Summary Paper No(s)/Mail Da	
	e of Draftsperson's Patent Drawing Review (PTO-948) matter Disclosure Statement(s) (PTO-1449 or PTO/SB/08)		ratent Application (PTO-152)
Pape	r No(s)/Mail Date	6) Cther;	

Art Unit: 1616

Claims 1-16 are pending in this application.

Claims 1-16 will continue to be examined to the extent that they read on the elected subject matter of record, sodium perborate + diethylene triamine penta(methylenephosphonic acid), hereinafter referred to as "DTPMP."

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-16 stand rejected under 35 U.S.C. 102(b) as being anticipated by Martin et al. (US 5,725,887) for the reasons of record.

Applicant's claim amendments and remarks relative hereto have been given due consideration, but they were deemed unpersuasive. The independent claims have been amended so that the solution pH is greater than 8.0. Applicant argues that Martin et al. do not disclose pH greater than 8.0. However, a close review of Martin et al. shows their pH to be between "about 5.5 and about 8" (emphasis added). See column 7, lines 16-17. The Examiner interprets "about 8" to be clearly inclusive of at least 8.01 or 8.1.1 For the term "about" to have any meaning at all, it must encompass a value

¹ Apparently, applicant intends "greater than 8.0" to be broad enough to still include pH 8.0. See dependent claims 2 and 12. Examiner's claim interpretation is further supported by applicant's own claims.

Art Unit: 1616

outside of 8.0. A value outside of 8.0 satisfies the amendatory feature, "pH greater than 8.0." Since a pH value that is outside of 8.0 such as pH 8.01 or 8.1 meets applicant's amendatory claim language, the disclosure by Martin et al. still anticipates the presently amended claims.

Claims 1-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Appleby et al. (US 5,827,808).

Appleby et al. explicitly discloses a dishwashing solution that contains sodium perborate + DTPMP². See formulations A, B, C, D, E and F on column 20. The formulations "have an unduly high pH, in preference having a pH measured as a 1% solution in distilled water of from 8.0 to 12.0, more preferably from 9.0 to 11.8, most preferably from 9.5 to 11.5" (column 18, lines 57-62). In the exemplified formulations A to F, supra, the 1% pH is 10.7 (see column 20, lines 28-29).

The claims are thereby anticipated. The following additional discussion is provided to further explain the basis for the anticipation of some of the dependent claim features.

Hydrogen peroxide from 2-100 ppm: The actual use-concentration of Appleby's formulation is in the range of 0.05-2% by weight (column 3, lines 30-35). Therefore, the pH measurement at the 1 wt% concentration is an accurate measurement of the actual

² Appleby et al. refer to DTPMP as "DETPMP." These are alternative names for the same compound.

Art Unit: 1616

use-composition that is also disclosed. In Appleby's formulations A to F, the 1 wt% diluted formulations would contain 0.012 wt% PB1, which is anhydrous sodium perborate monohydrate, which provides about 0.004 wt% hydrogen peroxide. This is equivalent to 40 ppm hydrogen peroxide.

pH between 8.0 and 9.5: The most preferred pH range of the aforementioned 1 wt% dilution is from 9.5 to 11.5 (column 18, lines 60-61). Therefore, at a minimum, pH 9.5 is explicitly disclosed.

As discussed above, all of the claimed features are explicitly disclosed by Appleby et al. The claims are anticipated.

Claims 2 and 12 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim.

Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

The independent claims have been amended to require the pH to be "greater than 8.0." Dependent claims 2 and 12 still read on "pH of between 8.0 and 9.5." If applicant intends 8.0 to be still within "greater than 8.0," the Examiner suggests amending the independent claims to read "greater than about 8.0."

Art Unit: 1616

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to JOHN PAK whose telephone number is (571)272-0620, effective February 3, 2004. The Examiner can normally be reached on Monday to Friday from 8 AM to 4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's SPE, Thurman Page, can be reached on (571)272-0602, effective February 3, 2004.

The fax phone number for the organization where this application or proceeding is assigned is (703)872-9306.

Art Unit: 1616

Page 6

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.

JOHN PAK PRIMARY EXAMINER GROUP (200

Notice of References Cited				1		Reexaminal	Applicant(s)/Patent Under Reexamination TSAO, FU-PAO	
	Notice of References Cited				Examiner Art Unit JOHN D PAK 1816			
							1	Page 1 of 1
L				U.S. P	ATENT DOCUM	ENTS		
*		Document Number Country Code-Number-Kind Code	Name			Classification		
	 			Appleb	by et al.			510/220
	В	US-						
	Ç	US-						
	D	US-						
Γ	Ε	US-						
	F	US-						
	G	US-						
	н	US-						
	1	US-						
	J	US-						
	К	US-				· · · · · · · · · · · · · · · · · · ·		
	L	US-						
	М	US-						
			• ••••	FOREIGN	PATENT DOC	UMENTS		
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	1	Country		me	Classification
*	N		Date	1	Country		sne	Classification
*	2 0		Date	1	Country		me	Classification
*	-		Date	1	Country		me	Classification
*	0		Date		Country		rite	Classification
*	O P		Date		Country		rite	Classification
*	O P Q		Date		Country		sri e	Classification
*	Ο P Q R		Date		Country			
	O P Q R	Country Code-Number-Kind Code	Date MM-YYYY	NON-P	ATENT DOCU	Na		
*	O P Q R	Country Code-Number-Kind Code	Date MM-YYYY	NON-P	ATENT DOCU	Na		
	O P Q R	Country Code-Number-Kind Code	Date MM-YYYY	NON-P	ATENT DOCU	Na		
	O P Q R S T	Country Code-Number-Kind Code	Date MM-YYYY	NON-P	ATENT DOCU	Na		
	P Q R S	Country Code-Number-Kind Code	Date MM-YYYY	NON-P	ATENT DOCU	Na		

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 05202004

5/690 Bldg. Room Rem

Organization / / / \(\begin{align*} \begin{align*} \eqric / \leftrightarrow \eqric \e

OMMISSIONER FOR PALENTS

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450 IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS



TECH CENTER 1800/2000

WOVASSS 679012044 1303 03 07/25/04
PORWARD TIME SXP KIN TO SEND
: WOVARTLE PERNANEUTICALS
1 REALTH PLZ
EAST HANOVER NO 07936-1016

RETURN TO SEIDER Hallahahahhahahahahah